Armata Pharmaceuticals, a late clinical-stage biotechnology company focused on developing bacteriophage-based therapies for antibiotic-resistant and difficult-to-treat bacterial infections, has received Fast Track Designation from the US Food and Drug Administration (FDA) for its investigational therapy AP-SA02.

The designation has been granted for the adjunct treatment of complicated bacteremia caused by Methicillin-Sensitive Staphylococcus Aureus (MSSA) and Methicillin-Resistant Staphylococcus Aureus (MRSA). AP-SA02 is an intravenously administered multi-phage therapeutic candidate specifically designed to target S. aureus infections.

The company stated that the FDA’s Fast Track Designation highlights the seriousness of complicated Staphylococcus aureus bacteremia and the urgent need for new treatment options for patients suffering from these severe bloodstream infections. Complicated S. aureus bacteremia is considered a life-threatening condition and remains associated with high mortality rates despite existing standard-of-care therapies.

Armata Pharmaceuticals noted that the designation recognises the potential of AP-SA02 to improve treatment outcomes compared to currently available therapies. The company also emphasised the growing importance of bacteriophage-based therapies as differentiated solutions for combating bacterial infections, particularly those involving antibiotic resistance.

Fast Track Designation is intended to accelerate the development and regulatory review of investigational treatments that address serious medical conditions and unmet clinical needs. Under the designation, Armata will benefit from more frequent interactions with the FDA throughout the clinical development process, enabling a potentially more efficient path toward regulatory approval.

The designation also allows the company to submit sections of its Biologics License Application (BLA) on a rolling basis rather than waiting to complete the full application before review. In addition, the programme may qualify for Accelerated Approval and Priority Review if supported by future clinical data.

Armata Pharmaceuticals plans to initiate a phase 3 superiority study for AP-SA02 during the second half of 2026 as it advances the therapy’s clinical development programme.

The company continues to focus on developing high-purity, pathogen-specific bacteriophage therapeutics aimed at addressing the global challenge of antibiotic-resistant bacterial infections and improving treatment options for critically ill patients.